Donanemab: A trailblazer for Alzheimer’s disease treatment?

FHS
July 20, 2023
10:55 am

A recent study evaluated the efficacy and side effects of donanemab, an antibody that could possibly clear brain amyloid plaque in early symptomatic Alzheimer disease (AD).

Teva’s new royalty deal; Selecta merges with Cartesian; Vir’s hepatitis data

Teva inks deal with Royalty Pharma for schizophrenia drug: The Israeli drugmaker said Monday that it will receive $100 million to complete an ongoing Phase

November 14, 2023

New gene therapy shows promise for treating fusion-driven cancers

A new study presents a promising treatment method for so-called fusion-driven cancers, which are currently often difficult to cure. These fusion-driven cancers are caused by

August 11, 2023

Long-term lung issues and lower quality of life plague COVID-19 survivors, new study warns

New research in Scientific Reports reveals that COVID-19 survivors, especially those who had severe or critical illness, face long-term lung complications and a reduced quality

October 15, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.